Girihlet

Founded in 2020 and based in San Francisco, Girihlet operates at the intersection of diagnostics, genetics, genomics, and AI-driven drug discovery. The company is building a multi-dimensional computational platform to discover new disease-monitoring and therapeutic strategies, with an initial focus on autoimmune diseases. A key near-term program is its ImmuneScanner diagnostic, which is being developed in collaboration with Mayo Clinic to monitor treatments for Ankylosing Spondylitis. Girihlet's approach positions it to leverage growing datasets in immunology to improve both clinical decision-making and pharmaceutical R&D.

A multi-dimensional, AI-powered computational biology platform that integrates diverse biological data to model the immune system, accelerating the discovery of disease-monitoring tools and therapeutic strategies.

Girihlet competes in the crowded AI-for-drug-discovery space against companies like Recursion, Exscientia, and Relay Therapeutics, as well as diagnostic firms focused on immune monitoring. Its differentiation hinges on a specialized focus on multi-dimensional immune system decoding and a dual diagnostic/discovery strategy.